Journal of Magnetic Resonance Imaging
October 1, 1999
L. Chang, Thomas Ernst, C.s. Grob et al.
28 citations
3,4-Methylenedioxymethamphetamine (MDMA) is an illicit drug that has been associated with serotonergic axonal degeneration in animals. This study evaluates neurochemical abnormalities in recreational MDMA users. Twenty-two MDMA users and 37 normal subjects were evaluated with magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy (1H MRS) in the mid-frontal, mid-occipital,...
Journal of Magnetic Resonance Imaging
October 1, 1999
L. Chang, Thomas Ernst, Charles S. Grob et al.
109 citations
3,4-methylenedioxymethamphetamine (MDMA) is an illicit drug that has been associated with serotonergic axonal degeneration in animals. This study evaluates neurochemical abnormalities in recreational MDMA users. Twenty-two MDMA users and 37 normal subjects were evaluated with magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) in the mid-frontal,...
Forensic Science International
September 30, 1999
Vittorio Fineschi, Fabio Centini, E Mazzeo et al.
Three fatal cases of MDMA/MDEA misuse have been examined. These referred to white males between 19 and 20 years of age, in which post-mortem toxicology showed the presence of MDMA (in one case), MDEA (in one case) and both (in one case). The clinical data were analysed and the histopathological findings were studied following immunohistochemical investigations. A complete immunohistochemical...
Journal of Pharmacology and Experimental Therapeutics
September 1, 1999
A. C. McCreary, M. G. Bankson, K. Cunningham
Activity in the periphery and center of an open field as well as rearing activity were measured in photobeam monitors. (1)-MDMA-induced peripheral and central activities were blocked by GR 127935 (0.3, 0.625, 1.25, and 2.5 mg/kg); central hyperactivity was blocked by 0.1, 0.3, and 0.625 mg/kg GR 127935. WAY 100635 (0.5–2 mg/kg) had little effect on (1)-MDMA-induced activity except for an...
Journal of Pharmacology and Experimental Therapeutics
July 1, 1999
M. Mas, M. Farré, Rafael de la Torre et al.
362 citations
The cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") were assessed in a double-blind, randomized, crossover, and controlled (placebo and amphetamine) clinical trial. Eight men with experience in the recreational use of MDMA participated in four 10-h experimental sessions with a 1-week washout period. Single oral doses of 125...
Clinical Chemistry
July 1, 1999
John K. Fallon, Andrew T. Kicman, J. A. Henry et al.
137 citations
Abstract Background: Little is known concerning the enantioselective disposition of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) in humans. In addition, the potential of utilizing the stereochemical composition of an analyte in biological media for forensic purposes requires investigation. Methods: The enantiomers of MDMA and its demethylated metabolite, 3,4-methylenedioxyamphetamine...
The British Journal of Psychiatry
July 1, 1999
David M. Semple, Klaus P. Ebmeier, Michael F. Glabus et al.
281 citations
Background The use of MDMA (‘ecstasy’) is common among young people in Western countries. Animal models of MDMA toxicity suggest a loss of serotonergic neurons, and potentially implicate it in the development of significant psychiatric morbidity in humans. Aims To test whether long-term use of MDMA can produce abnormalities in cerebral serotonin, but not dopamine, transporter binding measured...
Journal of Neuroscience
June 15, 1999
George Hatzidimitriou, Una D. Mccann, George A. Ricaurte
338 citations
The recreational drug (±)3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) is a potent and selective brain serotonin (5-HT) neurotoxin in animals and, possibly, in humans. The purpose of the present study was to determine whether brain 5-HT deficits persist in squirrel monkeys beyond the 18-month period studied previously and to identify factors that influence recovery of injured 5-HT axons....
Liver
June 1, 1999
G. Beitia, A. Cobreros, L. Sainz et al.
Abstract:Aims/Background: Hepatocellular damage has been reported as a consequence of 3,4‐methylenedioxymethamphetamine (MDMA) intake. However, little is known about the cellular mechanisms involved. The present study was undertaken to evaluate the effects of MDMA on cell viability as well as free calcium levels ([Ca2+]i) in short‐term cultured hepatocytes. Reduced glutathione (GSH),...
Pharmacology & Toxicology
June 1, 1999
María Isabel Colado, Raquel Ena María Granados, Esther O’shea et al.
26 citations
Abstract: Administration of a single dose of the recreationally used drug 3, 4‐methylenedioxyethamphetamine (MDEA or “eve”) to Dark Agouti rats resulted in an acute dose‐dependent hyperthermic response. The peak effect and duration of hyperthermia of a dose of MDEA of 35 mg/kg intraperitoneally was similar to a dose of 3, 4‐methylenedioxymetham‐phetamine (MDMA or “ecstasy”) of 15 mg/kg...